Pharmaceutical companies, academic researchers, and government agencies such as the Food and Drug Administration and the National Institutes of Health all possess large quantities of clinical research data. If these data were shared more widely within and across sectors, the resulting research advan
CNS Clinical Trials: Suicidality and Data Collection: Workshop Summary
โ Scribed by Forum on Neuroscience and Nervous System Disorders
- Publisher
- National Academies Press
- Year
- 2010
- Tongue
- English
- Leaves
- 88
- Edition
- 1
- Category
- Library
No coin nor oath required. For personal study only.
โฆ Synopsis
The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future.
๐ SIMILAR VOLUMES
Scientists and clinicians seek a new paradigm that could improve the efficiency, cost-effectiveness, and overall success rate of cancer clinical trials, while maintaining the highest standards of quality. To explore innovative paradigms for cancer clinical trials and other ways to improve their qual
For many, thoughts of suicide are abundant and frequent. There exists a fear of death but an even greater fear of life due to the latter's hardships. Participants of the committee on the Pathophysiology and Prevention of Adult and Adolescent Suicide of the Institute of Medicine's workshop on suicide
In 2011, the Institute of Medicine (IOM) released the report The Health of Lesbian, Gay, Bisexual, and Transgender People: Building a Foundation for Better Understanding, the first comprehensive compilation of what is known about the health of each of these groups at different stages of life. This r
In an effort to increase knowledge and understanding of the process of assuring data quality and validity in clinical trials, the IOM hosted a workshop to open a dialogue on the process to identify and discuss issues of mutual concern among industry, regulators, payers, and consumers. The presenters